Cassava Sciences Inc vs Financial Select Sector SPDR Fund — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Financial Select Sector SPDR Fund trades at $54.34 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 1270.6× Cassava Sciences Inc's market cap, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| FLNA | XLF | |
|---|---|---|
Market Cap | $39.40M | $50.06B |
Volume | 759,018 | 47,464,120 |
Sector | Health | — |
52-Week High | $4.64 | $58.55 |
52-Week Low | $0.68 | $47.80 |
Typical Hold Time | 37 Days | 104 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
XLF trades at $53.75, down 0.48% with bearish technical signals from moving averages. The financial sector faces headwinds as bank stocks lag the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create a mixed environment for financial institutions, with higher rates potentially benefiting some sector components while increasing borrowing costs.
The ETF's concentrated exposure to 76 large-cap financial firms positions it for potential gains from rising rates, though sector underperformance and regulatory uncertainty present near-term challenges. Fund managers increased financial allocations in Q2 2026, suggesting institutional confidence in the sector's rate sensitivity advantages over tech stocks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →